Clareo Health | Efficacy and Safety Study of Two Fixed-dose Combinations of Aclidinium Bromide With Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate and Placebo
Efficacy and Safety Study of Two Fixed-dose Combinations of Aclidinium Bromide With Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate and Placebo
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
Age
40–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Understand the study procedures and be willing to participate in the study as indicated by signing the ICF and HIPAA form
Be male or female aged 40 to 80 years, inclusive
Have a diagnosis of stable, moderate to severe COPD (stages II and III) as defined by guidelines of the Global Initiative for Chronic Obstructive Lung Disease (2008)
Be a current or former cigarette smoker with a smoking history of at least 10 pack-years
Have post-albuterol/salbutamol FEV1 values ≥ 30% and \< 80% of the predicted value. FEV1 will be measured at the Screening Visit (Visit 1) between 10 and 15 minutes after inhalation of albuterol/salbutamol.
If female, be at least 1 year postmenopausal or surgically sterile (defined as having a hysterectomy or tubal ligation). Women of childbearing potential must have a negative serum β-human chorionic gonadotropin pregnancy test at screening
Be in good stable health (as judged by the Investigator) other than the COPD, based on medical history, physical examination, ECG, spirometry, and clinical laboratory data evaluations
Have COPD symptoms and FEV1 values at the time of randomization that are stable compared with those at Screening (Visit 1), according to the Investigator's medical judgment
You may not be if
Have been hospitalized for an acute COPD exacerbation within 3 months before screening
Have any respiratory tract infection (including the upper respiratory tract) or signs of a COPD exacerbation or respiratory infection in the 6 weeks before Screening (Visit 1).
Have any clinically significant respiratory conditions other than COPD
Have a history or presence of asthma verified from medical records
Have used theophylline (including long-acting theophylline) within the previous 3 months before study entry
Have Stage II hypertension, defined as systolic pressure of 160 and above, and diastolic pressure of 100 and above
Chronic use of oxygen therapy ≥ 15 hours a day
Have a history, current diagnosis, or presence of exercise-induced bronchospasm
Have a body mass index ≥ 40 kg/m2
Have participated in an pulmonary rehabilitation program within the previous 3 months
Have clinically significant cardiovascular conditions
Have uncontrolled infection resulting from human immunodeficiency virus and/or active hepatitis
Have symptomatic prostatic hypertrophy and/or bladder neck obstruction.
Have narrow-angle glaucoma
Have a history of hypersensitivity reaction (including report of paradoxical bronchospasm) to inhaled anticholinergics (including aclidinium bromide), β2 adrenergic agonists, or any other inhaled medication or any component thereof
Have a QTcB, as indicated in the centralized reading report, above 470 msec in the resting ECGs performed at Screening (Visit 1) and/or patients who are using medications that may prolong the QT interval
Have clinically relevant abnormalities in the results of clinical laboratory tests, in ECG parameters other than QTc, in results of the physical examination,
Have any concurrent medical condition that, in the judgment of the Investigator, might interfere with the conduct of the study, confound the interpretation of the study results, or endanger the patient's well-being
Do not maintain regular day/night, waking/sleeping cycles (eg, patients with history of sleep apnea syndrome or any disease related with sleep disturbances such as restless legs syndrome or somnambulism)
